BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements

Compliance with Nasdaq Requirements - BeyondSpring Inc. has regained compliance with the minimum bid price requirement of Nasdaq, with the closing bid price of its ordinary shares being at $1.00 or greater for 10 consecutive business days from February 5, 2024, to February 16, 2024 [1] - The bid price deficiency matter previously disclosed is now closed [1] Periodic Filing Compliance - The company has met the periodic filing requirement for Nasdaq, having filed its Form 6-K for the period ended June 30, 2023, on February 2, 2024 [2] - The filing delinquency matter previously disclosed is now closed [2] Company Overview - BeyondSpring is a global clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with high unmet medical needs [3] - The company is advancing its lead asset, Plinabulin, as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia [3] - BeyondSpring's pipeline includes three preclinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which has a collaboration with Eli Lilly [3]